Does Lacosamide Interact with Common Cardiovascular Drugs?
Lacosamide, an antiepileptic drug (brand name Vimpat), has no absolute contraindications with cardiovascular medications, but it carries warnings for use with drugs that prolong the PR interval. This stems from lacosamide's own dose-dependent PR prolongation effect, which can lead to atrioventricular (AV) block, particularly at higher doses or in patients with underlying conduction issues.[1][2]
Prescribing information advises caution or ECG monitoring when combining lacosamide with:
- Beta-blockers like atenolol or metoprolol (mild PR prolongation risk).
- Calcium channel blockers such as verapamil or diltiazem (additive AV conduction slowing).
- Digoxin (increased risk of bradycardia or AV block).
- Class I and III antiarrhythmics, including propafenone, flecainide, and amiodarone.[1][3]
No severe interactions appear with statins, ACE inhibitors, or diuretics based on standard references.
What Happens in Patients with Heart Conditions?
Patients with severe conduction delays (e.g., second- or third-degree AV block) or sick sinus syndrome should avoid lacosamide altogether, regardless of other CV drugs, due to its cardiac effects. In trials, PR prolongation occurred in 8-25% of patients on 400-600 mg/day, with 0.2-0.5% discontinuing for AV block.[1][4] Combining with PR-prolonging CV drugs raises this risk, prompting recommendations for baseline ECGs and monitoring.
How Do These Interactions Compare to Other Antiepileptics?
Unlike carbamazepine (CYP3A4 inducer affecting many CV drugs) or phenytoin (similar enzyme effects), lacosamide has minimal CYP involvement, limiting pharmacokinetic clashes. Its main issue is pharmacodynamic—additive cardiac slowing—unlike lamotrigine, which rarely affects conduction.[2][5]
What Do Clinical Studies and Labels Say?
Phase 3 trials (SP667, SP754, SP755) showed no excess CV events with beta-blockers or calcium antagonists, but post-marketing reports include rare bradycardia cases with combinations.[1][4] FDA and EMA labels list these as precautions, not contraindications, with no dedicated black-box warning.[1][3]
[1]: Vimpat (lacosamide) Prescribing Information
[2]: Lexicomp: Lacosamide Drug Interactions
[3]: Drugs.com: Lacosamide Interactions Checker
[4]: Biton V, et al. Epilepsia 2007;48:393-407 (lacosamide CV safety).
[5]: Perucca E. CNS Drugs 2009;23:555-67 (epileptic cardiac effects comparison).